AFT Pharmaceuticals Limited — Director's Dealing 2021

Dec 22, 2021

==> picture [118 x 30] intentionally omitted <==

Ongoing Disclosure Notice Disclosure of Directors and Senior Managers Relevant Interests Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited;and
Name of listed issuer:		AFT Pharmaceuticals Limited(AFT)
Date this disclosure made:		22-Dec-21
Date of last disclosure:		3-Jul-20
Director or senior managergivingdisclosure
Full name(s):		Jon Lamb
Name of listed issuer:		AFT Pharmaceuticals Limited(AFT)
Name of related bodycorporate(if applicable):		Not applicable
Position held in listed issuer:		Director
Summary of acquisition or disposal of relevant interest(excluding specified derivatives)
Class ofaffected quotedfinancialproducts:		Fully-Paid OrdinaryShares in AFT
		Power to control the exercise of the right to vote
Nature of the affected relevant interest(s):		as trustee of the Rivers One Trust which holds the
		sharesin Rivers OneLimited
For that relevant interest-
Number heldinclass before acquisitionordisposal:		248,094
Number heldinclass afteracquisitionordisposal:		288,764
Current registeredholder(s):		N/A
Registeredholder(s) oncetransfers areregistered:		Rivers OneLimited
Details of transactionsgiving rise to acquisition or disposal
Total number of transactions to which notice relates:		1
Details of transactions requiring disclosure-
Date of transaction:		17-Dec-21
Nature of transaction:		On-market acquisition of ordinaryshares
Name of anyotherpartyorparties to the transaction(if known):		Not applicable
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or
disposal. If the consideration was not in cash and cannot be readily by converted into a
cash value,describe the consideration:		NZ$4.20per share
Number of financialproducts to which the transaction related:		40,670
If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period) include
thefollowing details—
Whether relevant interests were acquired or disposed of duringa closedperiod:		No
Whether prior written clearance was provided to allow the acquisition or disposal to proceed
duringthe closed period:		Not applicable
Date of the prior writtenclearance (ifany):		Not applicable
Summary of other relevant interests after acquisition or disposal:
Class ofquoted financialproducts:		Ordinaryshares
		Power to control the exercise of the right to vote or
Nature of relevant interest:		dispose of financialproduct
_For that relevant interest,- _
Number held in class:		26,305
Current registered holder(s):		Rivers Leigh Limited
For a derivative relevant interest,-
Type of derivative:		Not applicable
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (ifany):		Not applicable
Astatementastowhether the derivativeis cashsettled orphysically settled:		Not applicable
Maturity date of the derivative (ifany):		Not applicable
Expiry date of the derivative (ifany):		Not applicable
The price's specifiedterms (ifany):		Not applicable
Any other details needed to understand how the amount of the consideration payable under
the derivative or the value of the derivative is affected by the value of the underlying
financialproducts:		Not applicable
_For that derivative relevant interest,- _
Parties to the derivative:		Not applicable
If the director or senior manager is not a party to the derivative, the nature of the relevant
interestinthe derivative:		Not applicable
Certification
I certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all persons for
whom itismade.
Signature of director or officer:Malcolm Tubby - CFO
Date ofsignature:		22-Dec-21